Single-agent capecitabin maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of mCRC

被引：0
|
作者：
Xu, R. [1 ]
Li, Y. [1 ]
Luo, H. [1 ]
Wang, W. [2 ]
Wang, Z. [1 ]
Yuan, X. [3 ]
Ma, D. [4 ]
Wang, F. H. [1 ]
Zhang, D. [1 ]
Lin, D. R. [5 ,6 ]
Jia, J.
Hu, X. H. [7 ]
Peng, J. W. [8 ]
Lin, Y. C. [9 ]
机构：
[1] Sun Yat Sen Univ, Ctr Canc, Med Oncol, Guangzhou 510275, Guangdong, Peoples R China
[2] Foshan 1 Peoples Hosp, Med Oncol, Foshan, Peoples R China
[3] Huizhou Cent Hosp, Med Oncol, Huizhou, Peoples R China
[4] Guangdong Gen Hosp, Med Oncol, Huizhou, Peoples R China
[5] Jiangmen Cent Hosp, Med Oncol, Jiangmen, Peoples R China
[6] Dongguan Peoples Hosp, Med Oncol, Dongguan, Peoples R China
[7] Guangxi Med Univ, Canc Hosp, Med Oncol, Nanning, Peoples R China
[8] Zhongshan Peoples Hosp, Med Oncol, Zhongshan, Peoples R China
[9] Shantou Univ, Canc Hosp, Med Oncol, Shantou, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
142O
引用
收藏
页码：43 / 43
页数：1
相关论文
共 50 条
  • [1] Single-agent capecitabin maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer
    Xu, R.
    Yuhong, L.
    Huiyan, L.
    Wei, W.
    Zhiqiang, W.
    Xia, Y.
    Dong, M.
    Hua, W. Feng
    Dongsheng, Z.
    Daren, L.
    Chen, L. Yin
    Jun, J.
    Hua, H. Xiao
    Wen, P. Jie
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S373 - S374
  • [2] Continuing single-agent capecitabin as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer
    Xu, Rui-hua
    Li, Yu-hong
    Luo, Huiyan
    Wang, Wei
    Wang, Zhiqiang
    Yuan, Xia
    Wang, Fenghua
    Zhang, Dong-sheng
    Ma, Dong
    Lin, Da Ren
    Jia, Jun
    Hu, Xiao-hua
    Peng, Jie Wen
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [3] Continuing Single-Agent Bevacizumab as Maintenance Therapy After Induction XELOX (or FOLFOX) Plus Bevacizumab in First-Line Treatment of Metastatic Colorectal Cancer
    Diaz-Rubio, Eduardo
    ONCOLOGIST, 2012, 17 (11): : 1426 - 1428
  • [4] Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety
    Luo, H. Y.
    Li, Y. H.
    Wang, W.
    Wang, Z. Q.
    Yuan, X.
    Ma, D.
    Wang, F. H.
    Zhang, D. S.
    Lin, D. R.
    Lin, Y. C.
    Jia, J.
    Hu, X. H.
    Peng, J. W.
    Xu, R. H.
    ANNALS OF ONCOLOGY, 2016, 27 (06) : 1074 - 1081
  • [5] XELOX and bevacizumab followed by single-agent bevacizumab as maintenance therapy as first-line treatment in elderly patients with advanced colorectal cancer: the boxe study
    Gerardo Rosati
    Antonio Avallone
    Giuseppe Aprile
    Alfredo Butera
    Giorgio Reggiardo
    Domenico Bilancia
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 257 - 264
  • [6] XELOX and bevacizumab followed by single-agent bevacizumab as maintenance therapy as first-line treatment in elderly patients with advanced colorectal cancer: the boxe study
    Rosati, Gerardo
    Avallone, Antonio
    Aprile, Giuseppe
    Butera, Alfredo
    Reggiardo, Giorgio
    Bilancia, Domenico
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (01) : 257 - 264
  • [7] Preliminary efficacy of bevacizumab with first-line FOLFOX, XELOX, FOLFIRI and monotherapy for mCRC: First BEATrial
    Kretzschmar, A.
    Van Cutsem, E.
    Michael, M.
    Rivera, F.
    Berry, S.
    DiBartolomeo, M.
    Mazier, M.
    Lutiger, B.
    Cunningham, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [8] Preliminary efficacy of bevacizumab with first-line FOLFOX, XELOX, folfiri and monotherapy for MCRC: First beatrial
    Rivera, F.
    Van, Cutsem E.
    Kretzschmar, A.
    Berry, S.
    DiBartolomeo, M.
    Michael, M.
    Mazier, M.
    Lutiger, B.
    Cunningham, D.
    ANNALS OF ONCOLOGY, 2007, 18 : VII19 - VII19
  • [9] Preliminary efficacy of bevacizumab with first-line folfox, xelox, folfiri and fluoropyrimidines for mCRC: First BEAT trial
    Berry, S.
    Cunningham, D.
    Michael, M.
    Kretzschmar, A.
    Rivera, F.
    DiBartolomeo, M.
    Mazier, M.
    Lutiger, B.
    Van Cutsem, E.
    EJC SUPPLEMENTS, 2007, 5 (04): : 241 - 241
  • [10] First-Line XELOX Plus Bevacizumab Followed by XELOX Plus Bevacizumab or Single-Agent Bevacizumab as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: The Phase III MACRO TTD Study
    Diaz-Rubio, Eduardo
    Gomez-Espana, Auxiliadora
    Massuti, Bartomeu
    Sastre, Javier
    Abad, Albert
    Valladares, Manuel
    Rivera, Fernando
    Safont, Maria J.
    Martinez de Prado, Purificacion
    Gallen, Manuel
    Gonzalez, Encarnacion
    Marcuello, Eugenio
    Benavides, Manuel
    Fernandez-Martos, Carlos
    Losa, Ferran
    Escudero, Pilar
    Arrivi, Antonio
    Cervantes, Andres
    Duenas, Rosario
    Lopez-Ladron, Amelia
    Lacasta, Adelaida
    Llanos, Marta
    Tabernero, Jose M.
    Anton, Antonio
    Aranda, Enrique
    ONCOLOGIST, 2012, 17 (01): : 15 - 25
12345